An Unrestrictive New Approach That’s Redefining UnDruggable
Traditional target-based and phenotypic screening strategies have brought on an extraordinary wave of drug discovery. Today, nearly 600 proteins involved in a wide range of key therapeutic areas can be targeted.
But there’s a bigger wave of drug discovery coming.
And we are leading the way, powered by our novel photoaffinity-based chemoproteomics platform and our team of drug discovery mavericks.
Pushing the Boundaries of Current Drug Discovery
We’re here to unleash a pipeline of possibilities. Our integrated chemoproteomics-based drug discovery engine addresses the limitations of traditional screening approaches and enables, for the first time, the ability to target a broad swath of the “undruggable” proteome. Our platform helps rapidly identify actionable drug-like ligands for functional binding pockets on high-value protein targets.
What sets us apart
Explore the proteome
We’ve designed our proprietary library of non-covalent chemical probes for diversity. When coupled with our advanced chemoproteomics platform and sophisticated informatics, we gain the unique ability to define probe-protein interactions on a global scale, revealing novel druggable pockets across a complete range of mechanisms, including active sites, allosteric sites, and protein-protein interactions.
Capture high-value targets
We take target-centric and phenotypic-based approaches with our unique, expansive, and expanding library of universal affinity probes designed for diversity in drug-like space. Chemoproteomics-enabled targeted profiling and phenotypic screening represent powerful orthogonal approaches for the discovery of tractable ligands against high-value protein targets, with either genetic and/or pharmacological validation linking them to human pathophysiology. These include not just enzymes but transcription factors, channels, transporters, receptors, chaperones, uncharacterized proteins, and more.
Define the binding site
Our screening platform enables concurrent identification of binding sites within protein targets, accelerating an understanding of the mechanism of action, and facilitating structure-based drug design and downstream medicinal chemistry efforts.
Explore the proteome
We’ve designed our proprietary library of non-covalent chemical probes for diversity. When coupled with our advanced chemoproteomics platform and sophisticated informatics, we gain the unique ability to define probe-protein interactions on a global scale, revealing novel druggable pockets across a complete range of mechanisms, including active sites, allosteric sites, and protein-protein interactions.
Capture high-value targets
We take target-centric and phenotypic-based approaches with our unique, expansive, and expanding library of universal affinity probes designed for diversity in drug-like space. Chemoproteomics-enabled targeted profiling and phenotypic screening represent powerful orthogonal approaches for the discovery of tractable ligands against high-value protein targets, with either genetic and/or pharmacological validation linking them to human pathophysiology. These include not just enzymes but transcription factors, channels, transporters, receptors, chaperones, uncharacterized proteins, and more.
Define the binding site
Our screening platform enables concurrent identification of binding sites within protein targets, accelerating an understanding of the mechanism of action, and facilitating structure-based drug design and downstream medicinal chemistry efforts.
An Early-Stage Pipeline, Endless Possibilities
Our ligand library has successfully targeted a broad spectrum of different protein classes, including transcription factors, channels, transporters, receptors, chaperones, and more. We’ve used our platform to discover novel small molecule pockets and novel protein function modulators, further proof of our chemoproteomics approach.
